Modification of cardiovascular pharmacotherapy in palliative care patients with cancer- narrative review

Pasierski, Tomasz

doi:10.20452/pamw.4098

Cited by 6 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A review of pharmacotherapy for CVD in cancer patients requiring palliative care discussed the prognosis of cancer patients and the continuation of antihypertensive drugs. 271 All patients undergoing palliative care should be evaluated for the need for antihypertensive drugs and should be considered for discontinuation if only a few benefits are expected. If the end-of-life prognosis is fewer than 2 months, reducing and discontinuing all antihypertensive drugs should be considered if BP is normal.…”

Section: B Terminal State Of Cancermentioning

confidence: 99%

JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases

Anzai

Sato

Izumi

et al. 2021

Circ J

View full text Add to dashboard Cite

Section: B Terminal State Of Cancermentioning

confidence: 99%

JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases

Anzai

Sato

Izumi

et al. 2021

Circ J

View full text Add to dashboard Cite

“…A decision should be made on the possible termination of high-voltage therapy and limitation of the number of drugs applied to the minimum extent necessary. [19] The course of heart failure is much less predictable than the progress of disseminated cancer disease. Close cooperation between palliative medicine specialists and cardiology specialists is necessary.…”

Section: Discussionmentioning

confidence: 99%

An analysis of medical records of patients diagnosed with cardiomyopathy and provided with inpatient palliative care

Niemiec¹,

Siejak²,

Niemiec³

et al. 2020

Palliat Med Pract

View full text Add to dashboard Cite

Palliative care, currently also called 'supportive care', is a specialist care that focuses on improving the quality of life by relieving symptoms and stress in patients with an incurable disease. The actions taken are aimed at preventing suffering, treating pain and other somatic symptoms as well as at helping to solve psychosocial and spiritual problems, along with support for the patient's family. Heart failure caused by cardiomyopathy is an incurable disease that limits vital functions and is provided with guaranteed palliative and hospice care. This is a progressive disease and therapy only slows down its course, which means that the patient will be accompanied by the diagnosis throughout their whole life and this disease will be the cause of death in some cases. This article includes an analysis of the documentation of patients with cardiomyopathy, in whom standard methods of treatment, facilitating the improvement of heart function, proved to be ineffective. In order to improve the quality of life, patients were transferred to the Department of Palliative Medicine.

show abstract

“…15 Pasierski highlights the importance of reviewing and considering stopping antihypertensives for patients with a limited life expectancy. 16 Often towards the end of life there is a natural lowering of blood pressure putting those continuing to take these drugs at risk of hypotension (and dizziness and falls). 16 Gastric protection where there is no history of gastrointestinal bleeding, peptic ulcer, gastritis, or when taken to prevent side effects of other medications that have been ceased (eg steroids or nonsteroidal anti-inflammatory drugs) is likely to be unnecessary.…”

Section: Medication Classes Suitable For Deprescribingmentioning

confidence: 99%

“…16 Often towards the end of life there is a natural lowering of blood pressure putting those continuing to take these drugs at risk of hypotension (and dizziness and falls). 16 Gastric protection where there is no history of gastrointestinal bleeding, peptic ulcer, gastritis, or when taken to prevent side effects of other medications that have been ceased (eg steroids or nonsteroidal anti-inflammatory drugs) is likely to be unnecessary. 17 Oral hypoglycaemics may no longer be indicated if the sole use was secondary prevention of diabetic associated events or to treat mild hyperglycaemia.…”

Section: Medication Classes Suitable For Deprescribingmentioning

confidence: 99%

Deprescribing in palliative care

Thompson

2019

Clinical Medicine

View full text Add to dashboard Cite

The use of multiple medications is common in palliative care, putting patients at risk of adverse events and a high tablet burden. Deprescribing is the process of reviewing and stopping potentially inappropriate medications in order to improve quality of life. Barriers to deprescribing exist meaning many patients will take multiple medications despite being in the final months of life. The OncPal deprescribing guideline is a useful tool to support the process for patients with a limited life expectancy. There is evidence for the safety of stopping certain medications, particularly those aimed at primary prevention. A systematic process of reviewing individual medications and their appropriateness is recommended.

show abstract

Modification of cardiovascular pharmacotherapy in palliative care patients with cancer- narrative review

Cited by 6 publications

References 21 publications

JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases

JCS/JHFS 2021 Statement on Palliative Care in Cardiovascular Diseases

An analysis of medical records of patients diagnosed with cardiomyopathy and provided with inpatient palliative care

Deprescribing in palliative care

Contact Info

Product

Resources

About